Table of Contents Table of Contents
Previous Page  727 / 812 Next Page
Information
Show Menu
Previous Page 727 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S723

Conclusions

Mechanisms of hyponatremia in patients with

schizophrenia are not well clarified; nevertheless, dopamine seems

to be the common link between psychogenic polydipsia and

schizophrenia.

Keywords

Psychogenic Polydipsia; Hyponatremia;

Schizophrenia

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2155

EV1171

Treatment with intramuscular

paliperidone palmitate in

schizoaffective disorder

L. Maroto Martin

, P. Hervías Higueras

Hospital Doctor Rodríguez Lafora, Psiquiatría, Madrid, Spain

Corresponding author.

Introduction

Injectable formulations of long acting antipsychotic

are a valuable treatment option for patients with psychotic dis-

orders. Schizoaffective Disorder (SAD) is a complex disease; the

optimal treatment is not well established yet.

Objective

Answer the question about the effectiveness offered

by intramuscular Paliperidone Palmitate in SAD versus other

injectable antipsychotics. Keywords: schizoaffective disorder;

paliperidone palmitate injection.

Methods

A case report of a 35-year-old male diagnosed with

Schizoaffective Disorder six years ago and with personal history

of multiple manic decompensation after treatment discontinua-

tion. Throughout his life he has been treated with intramuscular

Risperidone 87.5mg (50 + 37.5) every 14 days, Olanzapine flas

20mg/day, Risperidone flas 3mg, Amisulpride 600mg/day, Val-

proic acid 1500mg/day Clonazepam 2mg/day and Lormetazepam

1mg. In the last admission one year ago, he started treatment

with intramuscular paliperidone palmitate up to 200mg a month.

Currently he receives a monthly dose of 100mg and concomitant

lithium 800mg/day.

Discussion

The use of intramuscular paliperidone palmitate in

SAD and its effectiveness against other injectable antipsychotic is

discussed.

Conclusions

The use of intramuscular paliperidone palmitate

appears to constitute an employment opportunity in the treatment

of intramuscular maintenance in SAD. It could be effective in stabi-

lizing episodes of acute exacerbation and remissions of psychotic,

manic and depressive symptoms.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2156

EV1172

Characteristics of violent

schizophrenic inpatients

R. Masmoudi

, F. Charfeddine , L. Aribi , F. Smaoui , E. Elleuch ,

J. Aloulou , O. Amami

Hédi Chaker University Hospital, Psychiatry “B”, Sfax, Tunisia

Corresponding author.

Introduction

Hetero-aggressive behavior is a frequent reason for

psychiatric hospitalization in patients with schizophrenia.

Aim

To describe the clinical and socio-demographic character-

istics of schizophrenic patients hospitalized following a violent

behavior.

Methods

It was a cross-sectional and descriptive study. It was

conducted in 32 patients diagnosed with schizophrenia, and hos-

pitalized in the psychiatry department “B” at the Hedi Chaker

University Hospital of Sfax in Tunisia during the month of August

2014. The reason for hospitalization was hetero aggressiveness.

Results

The average age of our patients was 36.19 years with a

male predominance (71.9%). Violent schizophrenic patients were

single (71.9%) and without occupation (68.8%). They have lived in

family in 81.3% of cases. They had a family history of psychiatric

disorders in 34.4% of cases, a criminal record in 25% of cases and

addictive behaviors in 71.9% of cases. Violent schizophrenics had

more than three psychiatric admissions in 50% of cases. They had

bad adherence to treatment (62.5%) and poor insight (87.5%). The

majority (90.6%) had a previous history of violent behavior. The

victim was a member of the patient’s family in 90%. At the time

of the incident, delusional syndrome was present in 78.1% of cases

and a mental automatism syndrome in 21.9% of cases.

Conclusion

Violence in patients with schizophrenia depends on

several factors such as poor insight, medication non-adherence and

a past history of violence. It is essential to assess the risk of vio-

lent behavior and act on the associated factors in order to prevent

recurrence of violence.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2157

EV1173

Battery of scales for comprehensive

assessment of social cognition,

neurocognition and motivation in

patients with schizophrenia

M. Minyaycheva

, K. Kiselnikova , O. Papsuev

Moscow Research Institute of Psychiatry, Outpatient Psychiatry and

Organization of Psychiatric Care, Moscow, Russia

Corresponding author.

Introduction

There has been a special interest in roles of neu-

rocognition, social cognition and motivation impairments in

patients with schizophrenia and possible approaches to remedi-

ating these deficits. Clinical practice lacks a comprehensive tool to

measure those deficits.

Objective

To build a comprehensive assessment battery to mea-

sure neurocognitive, social cognitive and motivational deficits in

order to form targets for remediation programs and assess their

efficiency.

Aims

Translation and adaptation for Russian speaking subjects

(if needed) of identified assessments upon authors’ agreement.

Methods

By consensus decision of 5 professionals in the field

of clinical psychiatry, psychology and neuroscience a number of

assessments were selectedwith the following criteria: 1. Relevance

to domain assessed, 2. Appropriateness for Russian social context,

3. Reference rates in scientific papers, 4. Time consumed by each

assessment.

Results

Six measures reflecting main domains (neurocognition,

Theory of Mind, attributional style, social perception, emotion pro-

cessing, motivation) were selected: 1. BACS (Brief Assessment of

Cognition in Schizophrenia) (R.S. Keefe et al., 2008), 2. Hinting

Task (R. Corcoran 1995), 3. AIHQ (Ambiguous Intentions Hostility

Questionnaire) (D.R. Combs et al., 2007), 4. RAD–15 (Relationships

Across Domains) (M. Sergi et al., 2004), 5. Ekman–60 (P. Ekman

et al., 1976), 6. AES (Apathy Evaluation Scale) (R.S. Marin et al.,

1991).

Conclusions

The battery built encompasses all targeted domains

of neurocognition, social cognition andmotivation. Time consumed

by the battery estimates 130

±

15minutes, which is appropriate

for clinical practice in a rehabilitation centre. Future research will

focus on patients profiling and shaping of rehabilitation programs

accordingly.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2158